Shares of Illumina Inc. (NASDAQ: ILMN) slumped as much as 8% on Monday after after Roche CEO Franz Humer said that a deal is now "off the table" because the U.S. genetics company is demanding too...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Illumina (ILMN) reported third quarter 2012 adjusted earnings per share (EPS) of 38 cents (excluding the impact of amortization of intangible assets), missing the Zacks...(read more
It was revealed on Monday that Illumina (NASDAQ: ILMN), which develops, manufactures and markets life science tools and integrated systems for the analysis of genetic...(read more
Illumina (ILMN) Company Overview
Illumina Inc. (Nasdaq: ILMN) manufactures instruments that are used to study DNA. The company's products allow researchers to study an individual's genetic makeup, sequence genomes, and determine the specific genetic causes of diseases. Illumina's systems have three components: readers, reagents, and one-time-use arrays. Much like its competitors Affymetrix and Applera, Illumina sells the readers at low margins and generates its revenue and income from the sale of disposable arrays and reagents, which are replaced after each procedure. Each reader generates approximately $600,000 in disposables revenue per year.
Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Illumina develops and commercializes sequencing technologies used to perform a range of analyses, including de novo sequencing, whole genome re-sequencing, gene expression analysis, and small RNA analysis. Its product and service offerings also include solutions for single-nucleotide polymorphism (SNP) genotyping, copy number variation (CNV), deoxyribonucleic acid (DNA) methylation studies, gene expression profiling, and low-multiplex analysis of DNA, small ribonucleic acid (RNA), and protein.
(Read more at Wikinvest )